NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Stride, Inc. (NYSE:LRN) securities. If you suffered a loss on your Stride investment and would like to explore a potential recovery […]

NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired StubHub Holdings, Inc. (NYSE:STUB) securities. If you suffered a loss on your StubHub Holdings, Inc. investment and would like to explore

NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ:SKYE) securities. If you suffered a loss on your Skye Bioscience, Inc. investment and would like to explore

NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Perrigo Company plc (NYSE:PRGO) securities. If you suffered a loss on your Perrigo Company plc investment and would like to explore

NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Freeport-McMoRan Inc. (NYSE:FCX) securities. If you suffered a loss on your Freeport-McMoRan Inc. investment and would like to explore a potential

NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Ltd. (NASDAQ:TLX) securities. If you suffered a loss on your Telix Pharmaceuticals Ltd. investment and would like to explore

(CNSX:DRUG.CN),(CNSX:DRUG),(NASDAQ:DRUG), BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure greater-than or equal to3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) GlobeNewswire January 06, 2026 BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure greater-than or equal

(NasdaqGM:ALVO),(Nasdaq First North Iceland:ALVO),(Stockholm:ALVO SDB), – Robert Wessman to continue serving as Executive Chairman in full-time capacity – Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior

NEW YORK, NY / ACCESS Newswire / January 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Integer Holdings Corporation (NYSE:ITGR) securities. If you suffered a loss on your Integer Holdings Corporation investment and would like to explore